OsmoPrep is a tablet colon prep. Not a liquid.
OsmoPrep Tablets are a simple, virtually tasteless way to prepare for your colonoscopy.
OsmoPrep Tablets are easy to take and are virtually tasteless. That's why more people who have taken OsmoPrep prefer
it over other forms of colonoscopy preparation. In fact, 95% of those who took OsmoPrep
would take it again for future
OsmoPrep Tablets are the latest advancement in the evolution of colonoscopy prep. Because OsmoPrep is a tablet
colon prep, not a liquid, the taste you experience is almost entirely from the clear liquid you take it with...not the prep.
In clinical trials, OsmoPrep demonstrated highly effective colon cleansing. This is the primary function of a colonoscopy
and an important first step for a successful colonoscopy.2
Clinical trials have also demonstrated that it is a
If you and your healthcare provider decide that OsmoPrep Tablets make sense for you in preparation for your colonoscopy
please follow his or her directions. Your healthcare provider knows what's best for you and how to achieve the best
results while taking any medication.
Learn how to take OsmoPrep Tablets.
Learn about the importance of hydration.
FAQ about OsmoPrep
Why do you need a bowel prep?
What happens during a colonoscopy?
Click to download important patient information about OsmoPrep.
Download Adobe Reader and Flash Player.
Important Safety Information about OsmoPrep
There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior
to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some
cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with
increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using
medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers
[ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).
It is important to use the dose and dosing regimen as recommended (PM/AM split dose).
Please see full Prescribing Information for OsmoPrep, including BOXED WARNING.
OsmoPrep® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing
of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OsmoPrep is used in
patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation,
bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal
function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte
disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as
hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OsmoPrep.
OsmoPrep is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with
biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were
abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OsmoPrep be advised to adequately hydrate before,
during, and after the use of OsmoPrep.
- Rex DK, Schwartz H, Goldstein M, et al. Safety and colon-cleansing efficacy of a new residue-free formulation of sodium phosphate tablets. Am J Gastroenterol. 2006;101:2594-2604.
- OsmoPrep Tablets [package insert]. Raleigh, NC: Salix Pharmaceuticals, Inc; 2011.